A clinical practice viewpoint: To culture or not to culture Helicobacter pylori?

Digestive and Liver Disease

Volumn 35, Issue 5, 2003, Pages 357-361

  Zullo, A ^a   Hassan, C ^a   Lorenzetti, R ^a   Winn, S ^a   Morini, S ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Bacterial culture; Endoscopy; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; RNA 23S; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TIME MANAGEMENT; TREATMENT FAILURE; UPPER GASTROINTESTINAL TRACT; BACTERIAL COUNT; GROWTH, DEVELOPMENT AND AGING;

COLONY COUNT, MICROBIAL; ENDOSCOPY, GASTROINTESTINAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0142056161     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00081-1     Document Type: Review

References (52)

1. Bizzozero G. Uber die Schlauchformigen drusen des Magendarmkanals und die Beziekungen ihres Epithels zu den Obserflchenepithel der Schleimhaut. Arch Mikr Anat 1893;42:82-94.
2. Krienitz W. Uber das Aufreiten von Spirochaten verschiedener Form im Megainhalt bei Carcinoma ventriculi. Deutsche Medizinische Wochenschrift 1906;28:872-90.
3. Marshall BJ. The Campylobacter pylori story. Scand J Gastroenterol 1988;23:58-66.
4. Marshall BJ, Warren RJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i:1311-4.
5. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric campylobacter. Med J Aust 1985;142:436-9.
6. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192-9.
7. Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, McConnel W, et al. Transfer of Campylobacter pylori and C. mustelae to Helicobacter gen. nov. as Helicobacter pylori comb, nov. and H. mustelae comb, nov., respectively. Int J Syst Bacteriol 1989;39:397-405.
8. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GC, Fleischmann RD, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47.
9. Ricci C, Menegatti M, Gatta L, Holton J, Moretti C, Vaira D. Pathogenesis of infection. In: Holton J, Vaira D, Mengatti M, Miglioli M, editors, Helicobacter pylori therapy: advances and opportunities, Milan: Mosby-Wolf, 1998, pp. 39-52.
10. McNulty CAM, Dent J, Fored GA, Wilkinson SP. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729-38.
11. Vaira D, Gatta L, Ricci C, D'Anna L, Miglioli M. Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 2001;33:788-94.
12. Malfertheiner P, Mégraud F, Morain CO, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
13. Caselli M, Parente F, Palli D, Covacci A, Alvisi V, Gasbarrini G, et al. Cervia working group report: guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig Liver Dis 2001;33:75-80.
14. Leung WK, Graham DY. Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol 2002;5:133-8.
15. Georgopoulos DS, Ladas SD, Karatapanis S, Triantafyllou K, Spiliady C, Mentis A, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002;16:569-75.
16. Gisbert JP, Gisbert JL, Marcos S, Garcia Gravalos R, Carpio D, Pjares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-6.
17. Zullo A, Hassan C, Campo SMA, Lorenzetti R, Febbraro I, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15:1193-7.
18. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-6.
19. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskava Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002;16:1277-82.
20. Huang JQ, Hunt RH. Treatment after failure: the problem of 'non-responders'. Gut 1999;45:140-4.
21. Owen RJ. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 2002;50:285-8.
22. Glupczynski Y. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing. In: Lee A, Megraus F, editors, Helicobacter pylori: techniques for clinical diagnosis and basic research, London: WB Saunders, 1996, pp. 17-33.
23. Owen RJ. Bacteriology of Helicobacter pylori. Balliere's Clin Gastroenterol 1995;9:415-46.
24. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 1997;41:735-9.
25. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role or omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
26. de Boer WA, van Etten RJXM, Coremans A, Schneeberger PM. Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylon infection. Aliment Pharmacol Ther 1998;12:77-81.
27. Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella Mele M, Bilardi C, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000;14:893-900.
28. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. GISU: prevalence of Helicobacter pylori resistance to antibiotics in North-east Italy: a multicentre study. Dig Liver Dis 2000;32:763-8.
29. Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, et al. Triple versus dual therapy for eradicating Helicobacter pylori and prevent-ing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998;93:584-90.
30. Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998;12:439-45.
31. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
32. Laurent J, Megraud F, Flejou JF, Caekaert A, Barthelemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dispepsia. Aliment Pharmacol Ther 2001;15:1787-91.
33. Realdi G, Dore MP, Piana A, Atzei A, Cugia L, Manca A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999;4:106-12.
34. Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 2002;40:649-52.
35. Eltaway AT. Prevalence of primary Helicobacter pylori resistance to several antimicrobials in a Saudi Teaching Hospital. Med Princ Pract 2002;11:65-8.
36. Kim JJ, Reddy R, Lee M, Kim JG, El Zaatari FA, Osato MS, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-61.
37. Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002;16:291-6.
38. Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002;19:155-8.
39. Wolle K, Leodolter A, Mafertheiner P, Konig W. Antibiotic suscep-tibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;51:705-9.
40. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a metaanalytical approach. Dig Dis Sci 2000;45:68-76.
41. van der Hulst RWM, Weel JFL, van der Ende A, ten Kate FJW, Dankert J, Tytgat GNJ. Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 1996;91:2333-7.
42. Romano M, Iovene MR, Montella F, Vitale LM, De Simone T, Del Vecchio BC, et al. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000;95:3317-8.
43. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates for Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
44. Lee JM, Breselin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13:489-96.
45. Nobata K, Ina K, Ohta M, Kawamura-Sato K, Tsuzuki T, Ando T, et al. Lower concentrations of clarithromycin suppress urease activity, motility, and binding to gastric epithelial cells in Helicobacter pylon isolates. Dig Liver Dis 2002;34:489-97.
46. Majewski SH, Goodwin CS. Restriction endonuclease analysis of the genome of Campylobacter pylori with rapid extraction method: evidence for considerable genomic variation. J Infect Dis 1988;157:465-71.
47. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990;34:1437-41.
48. Pedrazzoli J, Calafatti SA, Ortiz RA, Dias FE, Deguer M, Mendes FD, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001;36:51248-53.
49. McColl KEL, Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 2002;34:461-7.
50. Zullo A, Hassan C, Marignani M, Angeletti S, Morini S. A 10-day 'rescue' therapy for Helicobacter pylori eradication failure patients: preliminary data. Dig Liver Dis 2002;34:A19.
51. Zullo A, Hassan C, Lorenzetti R, Morini S. Helicobacter pylori eradication: do we have another ace up our sleeve? Dig Liver Dis 2001;33:805-6.
52. Monstein HJ, Mikpour-Badr S, Jansson J. Rapid molecular identification and subtyping of Helicobacter pylori by pyrosequencing of the 16S rDNA variable V1 and V3 regions. FEMS Microbiol Lett 2001;199:103-7.